MedTrace Logo

Galleri® in the Medicare Population.

NCT05673018 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50000

Last updated 2026-05-22

No results posted yet for this study

Summary

This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.

Conditions

Interventions

DEVICE

Multi-Cancer Early Detection Test (Galleri®)

Blood collection and multi-cancer early detection testing with return of results.

Sponsors & Collaborators

  • GRAIL, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-12
Primary Completion
2030-09-30
Completion
2030-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05673018 on ClinicalTrials.gov